Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics, Inc. (LXEO) registered securities for future offerings of up to $300,000,000 in the aggregate through a shelf covering common stock, preferred stock, debt securities, warrants, subscription rights, purchase contracts and units. Specific amounts, prices and terms will be set in prospectus supplements, and net proceeds from sales will go to Lexeo. The registration includes $135,387,220.20 of previously registered unsold securities; the earlier offering will be deemed terminated when this registration becomes effective.
Lexeo says its SUNRISE-FA 2 pivotal study of LX2006 is enrolling. Its finalized protocol and statistical analysis plan incorporate FDA feedback to date and are intended to support a BLA submission in the first half of 2028 under the accelerated approval pathway. LX2020 received FDA Regenerative Medicine Advanced Therapy designation in August 2026; Lexeo said it remained on track to provide a clinical and regulatory update in the fourth quarter of 2026. Prospectus supplements will describe intended use of net proceeds; pending their use, Lexeo intends to invest them in bank deposits, money market funds, treasury obligations and investment-grade securities.
Lexeo Therapeutics, Inc. (LXEO) common stock is the subject of a Schedule 13G in which JPMorgan Chase & Co. reports beneficial ownership of 4,573,701 shares, or 5.5% of the class. It reports sole voting power over 4,279,401 shares and sole dispositive power over 4,573,701 shares, with zero shared voting or dispositive power. The report identifies JPMorgan Chase Bank, National Association and J.P. Morgan Investment Management Inc. in the section concerning subsidiaries that acquired the securities.
Lexeo Therapeutics, Inc. (LXEO) completed its acquisition of Mantle Therapeutics Inc. on September 29, 2026. The aggregate upfront consideration was $5.3 million in cash, subject to certain adjustments, and $3 million in Lexeo common stock. Mantle remains the surviving corporation and a wholly owned subsidiary of Lexeo.
The merger agreement also provides for a one-time additional cash payment of $1 million upon specified events and up to $12 million in aggregate milestone payments tied to development and regulatory milestones over 12 years. These contingent payments are not guaranteed and may never become payable. Certain milestone payments are in cash and others in shares valued using a thirty-day trailing volume-weighted average price based on the milestone achievement date. The common stock issued in the merger was unregistered and issued in reliance on Section 4(a)(2) and/or Regulation D.
Lexeo Therapeutics, Inc. Chief Financial Officer Louis Edward Tamayo received a direct grant of 54,750 stock options on September 24, 2026, covering 54,750 shares of common stock and exercisable at $3.39 per share. Twenty-five percent of the underlying shares vest and become exercisable on September 24, 2027; 1/48th vests in monthly installments thereafter, subject to his continuous service. The options expire September 23, 2036.
Lexeo Therapeutics, Inc. Chief Medical Officer Narinder Pal Bhalla reported acquiring 2,714 common shares on September 14, 2026, under the company’s 2023 Employee Stock Purchase Plan at $3.579 per share. Reported holdings after that transaction were 84,908 shares, including 49,500 restricted stock units. On September 24, 2026, he reported an option grant covering 54,750 common shares, with a $3.39 exercise price and an expiration date of September 23, 2036.
Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero acquired 2,110 common shares under the 2023 Employee Stock Purchase Plan on September 14, 2026, at $2.644 per share. His reported common-stock holdings afterward were 138,288 shares, including 97,026 Restricted Stock Units. On September 24, 2026, he received an option covering 54,750 common shares at a $3.39 exercise price, expiring September 23, 2036. 25% of the underlying shares vest and become exercisable on September 24, 2027; 1/48th vests monthly thereafter, subject to continuous service. No Rule 10b5-1 plan is reported.
Lexeo Therapeutics, Inc.’s Chief Executive Officer and director, Richard Nolan Townsend, acquired 2,306 common shares on September 14, 2026, at $2.6440 per share through the 2023 Employee Stock Purchase Plan. His reported common-share holdings after that transaction were 376,778 shares, including 242,911 restricted stock units. On September 24, 2026, he received an option covering 145,500 common shares, with a $3.3900 exercise price and a September 23, 2036 expiration.
Lexeo Therapeutics, Inc. (symbol: LXEO) is the issuer of record for a Form 8-K filing submitted to the SEC.
Lexeo Therapeutics, Inc. (LXEO) reported that its Chief Financial Officer, Louis Edward Tamayo, sold 4,117 shares of common stock on 2026-08-18 at a weighted average price of $4.91 per share. According to the company’s disclosure, this sale represents shares sold to cover tax obligations arising from the release of restricted stock units. After this transaction, Tamayo directly holds 92,907 shares of Lexeo common stock, including 78,415 Restricted Stock Units.
Lexeo Therapeutics, Inc. (LXEO) reported that Chief Executive Officer and director Richard Nolan Townsend sold 3,345 shares of Common Stock on 2026-08-18. The sale, at a weighted average price of $4.9512 per share (individual trades ranged from $4.83 to $5.01), was to cover tax obligations on the release of restricted stock units (RSUs). Following this transaction, he directly holds 374,472 shares of Lexeo common stock, which includes 242,911 RSUs.